Welcome to our dedicated page for Neubase Therapeutics news (Ticker: NBSE), a resource for investors and traders seeking the latest updates and insights on Neubase Therapeutics stock.
Neubase Therapeutics Inc (NASDAQ: NBSE) is a biotechnology innovator focused on developing precision therapies for rare genetic disorders through its modular antisense platform. This page serves as the definitive source for all company announcements, research milestones, and financial updates.
Investors and researchers can access timely updates on clinical trial progress, strategic partnerships, and scientific advancements in gene silencing technology. Our curated news provides transparent insights into NBSE's efforts to address conditions like Huntington's disease through targeted genetic solutions.
Key content includes earnings reports, regulatory filings, technology patents, and collaboration announcements. Each update is verified for accuracy to support informed decision-making in genetic medicine.
Bookmark this page for direct access to Neubase's official communications. Check regularly for new insights into one of biotechnology's most promising approaches to treating inherited disorders.
NeuBase Therapeutics has appointed Dr. Sandra Rojas-Caro as Chief Medical Officer, effective May 24, 2021. Dr. Rojas-Caro brings over 20 years of drug development experience and will lead preclinical and clinical development for the company. Her expertise includes advancing therapies through regulatory approvals, and she aims to help NeuBase advance its first drug candidate into clinical trials next year. NeuBase focuses on precision genetic medicines targeting genetic diseases, with a mission to address undruggable oncogenic driver mutations.
NeuBase Therapeutics, Inc. (Nasdaq: NBSE) announced participation in two major events in May 2021. CEO Dietrich A. Stephan will engage in a virtual fireside chat at the RBC Capital Markets Virtual Global Healthcare Conference on May 19 at 11:30 a.m. ET. Additionally, he will present a corporate overview at the Oppenheimer Rare & Orphan Disease Summit on May 21. NeuBase focuses on developing precision genetic medicines targeting genetic diseases at the DNA or RNA level, aiming to address significant health challenges.
NeuBase Therapeutics (NBSE) reported a net loss of approximately $5.5 million for Q2 FY2021, alongside a strengthened cash position with $42.6 million from an equity offering. This funding supports advancing its lead program and expanding its precision genetic medicine pipeline. The company acquired peptide-nucleic acid technologies to enhance its platform and plans to host an R&D day on June 8 to present significant preclinical data, especially on myotonic dystrophy and Huntington's disease programs.
NeuBase Therapeutics (NASDAQ: NBSE) announced the appointment of Gerald McDougall to its Board of Directors. McDougall brings over 25 years of experience in strategic alliances and partnerships within the healthcare industry. He has previously led the Global Health Science consulting practice at PwC and has contributed to significant projects like TGen and MMRC. The Board anticipates that his extensive network and expertise will enhance NeuBase's approach to precision genetic medicine, aiming to address previously untreatable diseases through its PATrOL™ technology platform.
NeuBase Therapeutics (Nasdaq: NBSE) announces that CEO Dietrich A. Stephan will present at the B. Riley Securities’ Virtual Neuroscience Conference on April 29, 2021, at 10:30 a.m. ET. NeuBase focuses on developing innovative precision genetic medicines aimed at resolving genetic defects causing various diseases. The company’s unique PATrOL™ therapies target genetic diseases at the DNA or RNA level, particularly in neurological, neuromuscular, and oncologic disorders. For more details, visit www.neubasetherapeutics.com.
NeuBase Therapeutics (Nasdaq: NBSE) has successfully closed a public offering of 9.2 million shares of common stock at $5.00 per share, raising approximately $46.0 million. This offering included the exercise of an option for additional shares. The proceeds will be allocated for general corporate purposes, working capital, and further development of product candidates. The offering was managed by RBC Capital Markets, Oppenheimer & Co., and Chardan, with the registration statement filed with the SEC on April 1, 2021.
NeuBase Therapeutics (Nasdaq: NBSE) has priced an underwritten public offering of 8,000,000 shares of common stock at $5.00 per share, aiming for gross proceeds of approximately $40 million. The offering, expected to close on April 26, 2021, includes a 30-day option for underwriters to purchase an additional 1,200,000 shares. NeuBase plans to utilize the net proceeds for general corporate purposes and development of product candidates. The offering is being managed by RBC Capital Markets, Oppenheimer & Co., and Chardan.
NeuBase Therapeutics (Nasdaq: NBSE) announced an underwritten public offering of common stock, aiming to raise funds for general corporate purposes, working capital, and product development. Underwriters may purchase an additional 15% of shares sold. The offering is subject to market conditions and may vary in size and terms. RBC Capital Markets, Oppenheimer & Co., and Chardan are managing the offering. The shares will be sold under an effective shelf registration statement with the SEC.
NeuBase Therapeutics (Nasdaq: NBSE) announced a virtual R&D day for investors and analysts set for June 8, 2021, from 12:30 p.m. to 2:30 p.m. EDT. The event will showcase new data and provide a comprehensive review of the Company’s drug pipeline, including treatments for Huntington's disease, myotonic dystrophy type 1, and a new oncology program targeting previously undruggable conditions. The live webcast will be available on NeuBase's website, with a replay accessible for 90 days.
NeuBase focuses on precision genetic medicines to address genetic defects driving various diseases.
NeuBase Therapeutics announced an oral presentation at the 2021 Muscular Dystrophy Association Conference on March 18, 2021. The presentation, titled Resolution of Causality in Myotonic Dystrophy, Type 1 (DM1) via a PATrOL™-Enabled Therapy, will showcase preclinical data on their innovative PATrOL™ therapy for DM1 treatment. The presentation will be delivered by Dietrich A. Stephan, Ph.D., CEO of NeuBase, from 9:30 a.m. to 9:45 a.m. EDT. NeuBase focuses on genetic therapies aimed at addressing genetic defects using synthetic medicines. For more, visit neubasetherapeutics.com.
FAQ
What is the current stock price of Neubase Therapeutics (NBSE)?
What is the market cap of Neubase Therapeutics (NBSE)?
